Chronic Rhinosinusitis: Medical Management vs. Surgical Intervention

Abstract

Chronic rhinosinusitis (CRS) is a multifactorial inflammatory condition of the sinonasal mucosa, persisting for at least 12 weeks and significantly impacting patient quality of life. This review synthesizes current evidence comparing medical management and surgical intervention, with a focus on clinical effectiveness, underlying disease mechanisms, and guideline-based recommendations. By integrating insights from recent research and expert consensus, the article provides a comprehensive resource for clinicians navigating therapeutic decisions in CRS.

Introduction

Chronic rhinosinusitis remains a prevalent and challenging disorder in otolaryngology, characterized by persistent sinonasal inflammation, nasal obstruction, rhinorrhea, facial pain, and olfactory dysfunction. The disease imposes substantial health and economic burdens globally. Despite advances in understanding its pathophysiology, optimal management requires a nuanced approach tailored to patient phenotype, endotype, and response to initial therapies. This review critically evaluates the roles of medical and surgical interventions, referencing guideline updates and emerging data to inform clinical practice.

Epidemiology / Disease Burden

CRS affects approximately 10-12% of adults worldwide, with regional variations influenced by environmental, genetic, and socioeconomic factors. In the United States, CRS accounts for over 20 million outpatient visits annually and incurs direct and indirect costs exceeding $8 billion. The chronic symptom burden leads to lost productivity, impaired sleep, and comorbidities such as asthma and depression, underscoring the importance of effective management strategies.

Pathophysiology

CRS is broadly classified into two phenotypes: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). The pathophysiology involves persistent mucosal inflammation driven by complex interactions between host immune responses, environmental triggers, and microbial colonization. CRSwNP is frequently associated with type 2 inflammation, characterized by elevated eosinophils, interleukin (IL)-4, IL-5, and IL-13, whereas CRSsNP often exhibits neutrophilic inflammation. Impaired mucociliary clearance, epithelial barrier dysfunction, and dysbiosis of the sinonasal microbiome all contribute to disease chronicity.

Risk Factors

Risk factors for CRS include allergic rhinitis, asthma, aspirin-exacerbated respiratory disease (AERD), immunodeficiency, cystic fibrosis, environmental exposures (e.g., tobacco smoke, air pollution), and structural anomalies such as septal deviation. Genetic predisposition and occupational factors also modulate individual susceptibility and disease severity.

Clinical Features

Patients with CRS typically present with nasal congestion, discolored nasal discharge, facial pain or pressure, and reduced or lost sense of smell. Additional features may include postnasal drip, cough, fatigue, and dental pain. Symptomatology varies between CRSwNP and CRSsNP, with polypoid disease more often causing anosmia and severe obstruction. The chronic nature of symptoms, persisting beyond 12 weeks, distinguishes CRS from acute rhinosinusitis.

Diagnosis

Diagnosis of CRS is established based on a combination of clinical criteria and objective findings. The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) and American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) guidelines recommend symptom assessment, nasal endoscopy, and imaging when indicated. Nasal endoscopy allows direct visualization of mucosal edema, polyps, or purulent secretions, while computed tomography (CT) delineates the extent of mucosal disease and guides surgical planning.

Treatment & Management

Medical management is first-line and aims to control inflammation, restore sinus drainage, and reduce symptom burden. Key modalities include intranasal corticosteroids, saline irrigations, short courses of oral corticosteroids (for severe inflammation), and antibiotics for suspected bacterial exacerbations. Adjunct therapies such as antihistamines, leukotriene modifiers, or antifungals may be considered in select cases. Failure of maximal medical therapy prompts consideration of surgical intervention, typically functional endoscopic sinus surgery (FESS), which aims to improve sinus ventilation, facilitate topical drug delivery, and remove obstructive polyps or diseased tissue.

Recent Advances / Emerging Therapies

Recent years have seen significant advances in the pharmacological armamentarium for CRS, particularly for CRSwNP. Biologic therapies targeting key inflammatory pathways—such as anti-IL-5 (mepolizumab), anti-IL-4Rα (dupilumab), and anti-IgE (omalizumab)—have demonstrated efficacy in reducing polyp burden, improving symptoms, and decreasing the need for surgery in refractory cases. Innovations in drug delivery systems, such as exhalation delivery devices and drug-eluting implants, are improving local corticosteroid delivery to sinonasal tissues. Research is ongoing into modulation of the sinonasal microbiome and novel anti-inflammatory agents.

Guideline Recommendations

Current guidelines from EPOS 2020 and AAO-HNS endorse a stepwise approach: initiate with maximal medical therapy, escalating to FESS for patients with persistent symptoms and objective evidence of disease. Biologics are recommended for select patients with severe CRSwNP refractory to conventional therapies, with careful consideration of cost, access, and long-term safety. Postoperative care, including continued topical therapies, is essential to maintain surgical benefits and prevent recurrence.

Conclusion

Chronic rhinosinusitis management requires a comprehensive, individualized approach integrating medical and surgical modalities based on disease phenotype, severity, and patient-specific factors. While most patients benefit from optimized medical therapy, surgical intervention remains indispensable for refractory cases and for facilitating further topical treatment. Emerging biologic and targeted therapies hold promise for patients with recalcitrant disease, yet cost-effectiveness and long-term outcomes warrant ongoing evaluation. Clinicians must remain abreast of evolving evidence and guideline updates to provide optimal, patient-centered care.